Kissei Pharmaceutical Co., Ltd. Provides Consolidated Earnings Guidance for the First Half and Full Year of Fiscal Year Ending March 31, 2024
May 09, 2023 at 02:00 am EDT
Share
Kissei Pharmaceutical Co., Ltd. provided consolidated earnings guidance for the first half and full year of fiscal year ending March 31, 2024. For the first half, the company expects net sales of JPY 35,500 million, operating profit of JPY 900 million, profit attributable to owners of parent of JPY 4,800 million and basic earnings per share of JPY 104.09.
For the full year, the company expects net sales of JPY 74,500 million, operating profit of JPY 4,200 million, profit attributable to owners of parent of JPY 10,600 million and basic earnings per share of JPY 229.86.
KISSEI PHARMACEUTICAL CO.,LTD. is a Japan-based company mainly engaged in the manufacture and sale of pharmaceutical products. The Company is engaged in the collection and analysis of medicine development information, and the manufacture and sale of medicines. It is also engaged in the purchase and sale of related materials, system development and information process work, construction contract work such as new construction, expansion and renovation of factories, laboratories and offices, the management of facility and equipment work, information collection and development support work, noodle manufacture and sale, and insurance agency business.
KISSEI PHARMACEUTICAL CO., LTD. 
